logo
Plus   Neg
Share
Email

Axsome Reports Positive Results From Phase 3 Trial Of AXS-07 In Acute Treatment Of Migraine

Axsome Therapeutics Inc. (AXSM) announced positive efficacy and safety results from phase 3 movement long-term trial of AXS-07 in the acute treatment of migraine.

According to the company, treatment with AXS-07, rapidly, substantially, and durably relieved migraine pain and associated symptoms in this trial. AXS-07 was well tolerated over long-term treatment with a safety profile consistent with that observed in the previously reported controlled trials.

Two hours after administration of AXS-07, relief of migraine pain was achieved by 68% of patients and pain freedom by 38% of patients.

AXS-07 durably relieved migraine pain with 85% of patients free from rescue medication use through 24 hours, and 83% of patients free from rescue medication use through 48 hours after a single administration of AXS-07.

AXS-07 was well tolerated with long-term dosing. The safety profile of AXS-07 over the 12-month treatment period was consistent with that previously reported in short-term controlled trials.

Axsome said it remains on track to submit an new drug application or NDA for AXS-07 in the acute treatment of migraine in the first quarter of 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Uber Technologies Inc. (UBER) Wednesday reported a first-quarter loss that narrowed from last year, despite revenues dropping 16%, reflecting a gain from sale of self-driving unit. The ride-hail service's fourth-quarter loss was narrower than Wall Street estimates, but revenues fell short of expectations.... Social media giant Facebook's Workplace business tool has breached the seven million paid subscribers mark at a time when jobs have gone remote and is now the new normal amid the ongoing pandemic. The number of paid subscribers has grown 40 percent from last year. General Motors Co. (GM) Wednesday reported a profit for the first-quarter that surged from last year, driven by strong price and mix performance in North America, strong credit and residual value performance at GM Financial, as well as the industry recovery in China. Earnings per share topped analysts' expectations, while quarterly revenues missed their estimates.
Follow RTT